Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial
In a randomized controlled trial, Caroline Crowther and colleagues examine the effect of vaginal progesterone pessaries for pregnant women to prevent neonatal respiratory distress syndrome.
Vyšlo v časopise:
Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. PLoS Med 14(9): e32767. doi:10.1371/journal.pmed.1002390
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002390
Souhrn
In a randomized controlled trial, Caroline Crowther and colleagues examine the effect of vaginal progesterone pessaries for pregnant women to prevent neonatal respiratory distress syndrome.
Zdroje
1. March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global Action Report of Preterm Birth. Eds Howsom CP, Kinney MV, Lawn JE. WHO, Geneva, 2012.
2. Colicchia LC, Simhan HN. Optimizing subsequent pregnancy outcomes for women with a prior preterm birth. American Journal of Perinatology. 2016;33(3):267–75. doi: 10.1055/s-0035-1571143 26808194
3. Laughon SK, Albert PS, Leishear K, Mendola P. The NICHD Consecutive Pregnancies Study: recurrent preterm delivery by subtype. American Journal of Obstetrics and Gynecology. 2014;210(2):131.e1–8.
4. Yang J, Baer RJ, Berghella V, Chambers C, Chung P, Coker T, et al. Recurrence of preterm birth and early term birth. Obstetrics and Gynecology. 2016.
5. Gibson AM, Doyle LW. Respiratory outcomes for the tiniest or most immature infants. Seminars in Fetal & Neonatal Medicine. 2014;19(2):105–11.
6. Chow SSW, Le Marsney R, Hossain S, Haslam R, K L. Report of the Australian and New Zealand Neonatal Network 2013. Sydney: ANZNN, 2015.
7. Saigal S, Doyle L. An overview of mortality and sequelae of pretrem birth from infancy to adulthood. Lancet 2008;371:261–9. doi: 10.1016/S0140-6736(08)60136-1 18207020
8. Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature. 1998;392(6675):509–12. doi: 10.1038/33176 9548257
9. Williams KC, Renthal NE, Condon JC, Gerard RD, Mendelson CR. MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(19):7529–34. doi: 10.1073/pnas.1200650109 22529366
10. Nadeem L, Shynlova O, Matysiak-Zablocki E, Mesiano S, Dong X, Lye S. Molecular evidence of functional progesterone withdrawal in human myometrium. Nature communications. 2016;7:11565. doi: 10.1038/ncomms11565 27220952
11. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocrine Reviews. 1995;16(5):608–48. doi: 10.1210/edrv-16-5-608 8529574
12. Pieber D, Allport VC, Hills F, Johnson M, Bennett PR. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction. 2001;7(9):875–9. 11517295
13. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990; 97: 149–54. 2138496
14. Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD004947. doi: 10.1002/14651858.CD004947.pub3 23903965
15. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. American Journal of Obstetrics and Gynecology. 2003;188(2):419–24. 12592250
16. O'Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2007;30(5):687–96.
17. American College of Obstetricians and Gynecologists. Prediction and prevention of preterm birth. ACOG 2012.
18. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Progesterone: Use in the second and third trimester of pregnancy for the prevention of preterm birth. RANZCOG Melbourne: Women's Health Committee, 2013.
19. Royal College of Obstetricians and Gynaecologists. Communication on the Use of Progesterone to Prevent Preterm Delivery. London: RCOG 2010.
20. Society for Maternal-Fetal Medicine Publications Committee, with the assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. SMFM Clinical Guideline. American Journal of Obstetrics & Gynecology 2012;206(5):376–386. doi: 10.1016/j.ajog.2012.03.010 22542113
21. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. The New England Journal of Medicine. 2003;348(24):2379–85. doi: 10.1056/NEJMoa035140 12802023
22. Dodd JM, Crowther CA, McPhee AJ, Flenady V, Robinson JS. Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial. BMC pregnancy and childbirth. 2009;9:6. doi: 10.1186/1471-2393-9-6 19239712
23. Ware JE, Sherbourne CD. The MOS 36 item short form health survey (SF36) conceptual framework and item selection. Medical Care 1992;30:473–483. 1593914
24. Marteau TM, Bekker H. The development of a six item form of the State Scale of the Spielberger State Trait Anxiety Inventory (STAI). Br J Clin Psychology 1992;31:301.
25. Cox JL. Detection of postnatal depression—development of the 10 item Edinburgh Postnatal Depression Scale (EDPS). Brit J Psych 1987;154:782–786.
26. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005; 365:1348–1353. doi: 10.1016/S0140-6736(05)61034-3 15823387
27. Lei B, Mace B, Dawson HN, Warner DS, Laskowitz DT, James ML. Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated bv-2 microglia. PLoS ONE. 2014;9: e103969. doi: 10.1371/journal.pone.0103969 25080336
28. Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet (London, England). 2016;387(10033):2106–16.
29. Akbari S, Birjandi M, Mohtasham N. Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences. 2009;14(3):11–9.
30. Majhi P, Bagga R, Kalra J, Sharma M. Intravaginal use of natural micronised progesterone to prevent pre-term birth: A randomised trial in India. Journal of Obstetrics and Gynaecology 2009;29:6, 493–498, doi: 10.1080/01443610902980878 19697195
31. Cetingoz E, Cam C, Sakalh M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet 2011;283:423–429. doi: 10.1007/s00404-009-1351-2 20091317
32. Azargoon A, Ghorbani R, Aslebahar R. Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: A randomized placebo-controlled double-blin study. Int J Reprod BioMed 2016;14(5):309–316.
33. Duley L, Uhm S, and Oliver S. Top 15 UK research priorities for preterm birth, on behalf of the Preterm Birth Priority Setting Partnership Steering Group. Lancet. 2014; 383: 2041–2042.
34. Addressing Disparities Program—PCORI www.pcori.org/…/PCORI-Addressing-Disparities-Advisory-Panel-Fall-2016. Pg 106. Pilot IPD-MA project on progesterone and preterm birth with MOD and NIHR.
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2017 Číslo 9
- Statinová intolerance
- Hydroresponzivní krytí v epitelizační fázi hojení rány
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Effectiveness of food supplements in increasing fat-free tissue accretion in children with moderate acute malnutrition: A randomised 2 × 2 × 3 factorial trial in Burkina Faso
- Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study
- Keeping it real: A journal editor in clinic
- Sustained effectiveness and cost-effectiveness of Counselling for Alcohol Problems, a brief psychological treatment for harmful drinking in men, delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial